Groundbreaking Vaccine Approved to Protect Koalas from Chlamydia

Strategic Insights -

In a world first, the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved a vaccine to protect koalas from infection and death caused by chlamydia. Developed by the University of the Sunshine Coast (UniSC), the vaccine is a major breakthrough in the fight against one of the greatest threats to the long-term survival of Australia's iconic marsupial. The single-dose vaccine, led by Professor of Microbiology Peter Timms, has been in development for over 10 years and has shown remarkable effectiveness in reducing the spread of the disease.

Key Takeaways:

  • The vaccine has been approved by the APVMA for production and widespread use under its minor use category, making it the first-ever vaccine to protect koalas from chlamydia.
  • The vaccine is a single-dose vaccine, designed to cover the different strains of chlamydia circulating in different parts of the country, and offers three levels of protection: reducing infection, preventing progression to clinical disease, and reversing existing symptoms.
  • The vaccine has been trialled on hundreds of wild koalas, others in captivity and wildlife hospitals, and over multiple generations, with a studies showing it reduced the likelihood of koalas developing symptoms of chlamydia during breeding age by at least 65%.
  • The vaccine was developed through a partnership between UniSC, Treidlia Biovet, and the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO), with funding from the Bill and Melinda Gates Foundation, CEVA Wildlife Research Fund, and other organizations.
  • The vaccine highlights the University's strategic focus on working collaboratively to find solutions to some of the world's most pressing ecological and health challenges, and is a tangible, game-changing product that promises to ensure a future for the koala species.

Statistics:

  • Over 10 years, UniSC's researchers spent on the development of the vaccine.
  • The vaccine has been trialled on hundreds of wild koalas.
  • The vaccine has shown a 65% reduction in mortality from the disease in wild populations.
  • $76 million has been invested by the Albanese Government's Saving Koalas Fund.
  • $39.6 million has been committed to expand protected areas in Queensland.
  • $39.6 million has been committed to enhance key wildlife hospital facilities in South East Queensland.

Sources:

  • University of the Sunshine Coast
  • Australian Pesticides and Veterinary Medicines Authority
  • Treidlia Biovet
  • University of Saskatchewan's Vaccine and Infectious Disease Organization
  • Bill and Melinda Gates Foundation
  • CEVA Wildlife Research Fund
  • Federal Department of Climate Change, Energy, the Environment and Water
  • Queensland Department of Environment and Science
  • Department of Transport & Main Roads
  • NSW State Government - Koala Research Plan Team
  • City of Gold Coast
  • Redland City Council
  • City of Moreton Bay
  • Endeavour Veterinary Ecology
  • Australia Zoo Wildlife Hospital and Australia Zoo
  • RSPCA
  • Moggill Koala Rehab Centre
  • State Government (koala vaccine trials)
  • Friends of Koala, Lismore
  • Lone Pine Koala Sanctuary
  • Port Macquarie Koala Hospital